Table 1. Patient and tumor characteristics at diagnosis for all patients with resectable pancreatic adenocarcinoma treated with neoadjuvant chemotherapy (n=36).
| Characteristics | Entire cohort (n=36) | Gemcitabine (n=17) | Multi-agent (n=19) | P value |
|---|---|---|---|---|
| Age (median, IQR) | 66.3 (61.3–74.0) | 65.6 (61.3–70.64) | 66.9 (61.6–75.85) | 0.84 |
| Sex, male, n (%) | 23 (63.9) | 10 (58.8) | 13 (68.4) | 0.60 |
| Race, White, n (%) | 34 (94.4) | 16 (94.1) | 18 (94.7) | 0.99 |
| Year of diagnosis, n (%) | 0.02 | |||
| 2012–2014 | 18 (50.0) | 12 (79.6) | 6 (31.6) | |
| 2015–2016 | 18 (50.0) | 5 (29.4) | 13 (68.4) | |
| Comorbidity, n (%) | 0.99 | |||
| None [0] | 6 (16.7) | 3 (17.6) | 3 (15.8) | |
| Mild [1] | 20 (55.6) | 9 (52.9) | 11 (57.9) | |
| Moderate [2] | 8 (22.2) | 4 (23.5) | 4 (21.1) | |
| Severe [3] | 2 (5.6) | 1 (5.9) | 1 (5.3) | |
| Obese, BMI ≥30, n (%) | 6 (16.7) | 3 (17.6) | 3 (15.8) | 0.99 |
| DM, n (%) | 8 (22.2) | 4 (23.5) | 4 (21.1) | 0.99 |
| Tumor location, head, n (%) | 29 (80.6) | 16 (94.1) | 13 (68.4) | 0.09 |
| Clinical T stage, n (%) | 0.16 | |||
| T1 | 8 (22.2) | 6 (35.3) | 2 (10.5) | |
| T2 | 13 (36.1) | 6 (35.3) | 7 (36.8) | |
| T3 | 15 (41.7) | 5 (29.4) | 10 (52.6) | |
| Clinical N stage, n (%) | 0.41 | |||
| N0 | 31 (86.1) | 16 (94.1) | 15 (78.9) | |
| N1 | 5 (13.9) | 1 (5.9) | 4 (21.1) | |
| Tumor size (median, IQR) | 2.5 (2.00–3.02) | 2.1 (1.7–2.60) | 2.8 (2.40–3.30) | 0.06 |
| CA19-9, U/mL (median, IQR) | 96.0 (26.0–322.0) | 86.5 (15.5–271.5) | 154.0 (44.0–323.0) | 0.51 |
| Albumin, g/dL (median, IQR) | 3.6 (3.35–3.85) | 3.65 (3.45–3.97) | 3.5 (3.35–3.75) | 0.26 |
BMI, body mass index; DM, diabetes mellitus.